, Tracking Stock Market Picks
Enter Symbol:
Xoma Ltd. (XOMA) [hlAlert]

down 98.17 %

Xoma Ltd. (XOMA) rated Buy by Canaccord Adams

Posted on: Wednesday,  Nov 18, 2009  8:25 AM ET by Canaccord Adams

Canaccord Adams rated Buy Xoma Ltd. (NASDAQ: XOMA) on 11/18/2009. Previously Canaccord Adams rated Buy Xoma Ltd. (NASDAQ: XOMA) on 11/27/2007.,
when the stock price was $45.60. Since then, Xoma Ltd. has lost 98.18% as of 11/27/2015's recent price of $0.83.
If you would have followed the previous Canaccord Adams's recommendation on XOMA, you would have lost 98.17% of your investment in 2922 days.

XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies, with a therapeutic focus that includes cancer and immune diseases. XOMA has royalty interests in RAPTIVA, a monoclonal antibody product marketed worldwide to treat moderate-to-severe plaque psoriasis, and LUCENTIS, a monoclonal antibody product marketed worldwide to treat neovascular age-related macular degeneration. The company has built a premier antibody discovery and development platform that includes access to seven of the leading commercially available antibody phage display libraries and XOMA's proprietary Human Engineering and bacterial cell expression technologies. More than forty five companies have signed BCE licenses. XOMA's development collaborators include Lexicon Genetics, Inc., Novartis, and Schering-Plough Corporation. With a fully integrated product development infrastructure, XOMA's product development capabilities extend from preclinical sciences to product launch.

Canaccord Adams provides focused, actionable, idea-driven research, helping clients make informed investment decisions. Our 55 international analysts scour the globe for emerging and small to mid cap (US$1-2 billion market capitalization) growth opportunities, identifying value and exposing risk. Our research team analyzes over 550 companies in eight sectors, clarifying current events and anticipating market trends in high-quality daily, weekly and monthly research products. Our clients benefit from our thorough and sophisticated knowledge of the sectors we cover - Metals and Mining, Energy, Technology, Life Sciences, Real Estate, Consumer, Sustainability and Industrial Growth. We combine independent, actionable ideas, unique global perspective and unparalleled industry expertise. We believe it's evident in our research, and the foundation of our business.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/18/2009 8:25 AM Buy
as of 12/31/2009
1 Week down  -42.94 %
1 Month down  -48.26 %
3 Months down  -52.09 %
1 YTD down  -37.41 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/27/2007 9:25 AM Buy
45.60 70.50

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy